[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"duchenne--becker-muscular-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:duchenne--becker-muscular-dystrophy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100624915","evaluation-of-the-role-of-mir-1-in-the-pathogenesis-and-as-a-biomarker-in-muscular-dystrophies-and-congenital-myopathies-100624915",false,"NCT07415837","Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies","Dystro-miR1","Inclusion Criteria:\n\n* Age: Participants must be older than 2 years of age\n* Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,.\n* Social Security: Every participant must be affiliated with the French social security system.\n* Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.\n\nExclusion Criteria:\n\n* Refusal to participate expressed by the subject or their parental authority.\n* Engaging in intense and unusual physical effort within 10 days before the blood draw.\n* Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results.\n* Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection.\n* Women who are pregnant or breastfeeding.\n* The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings",true,"ALL","2 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.\n\nMicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.\n\nThe main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:\n\n1. Patients with Duchenne or Becker muscular dystrophy (DMD\u002FDMB).\n2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease).\n3. Patients with congenital myopathies.\n4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.",[27,28,29,30],"Duchenne \u002F Becker Muscular Dystrophy","Dystrophia Myotonica 1","Congenital Myopathies","Healthy Participants",[32,33,34],"biomarkers","neuromuscular diseases","micro-RNAs","RECRUITING","2026-02-24",{"date":38,"type":39},"2026-02-25","ACTUAL",{"date":41,"type":39},"2026-02-11",{"date":43,"type":21},"2029-03",{"name":45,"class":46},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100600722","transition-to-adulthood-in-people-with-muscular-dystrophy-100600722","NCT07101185","Transition to Adulthood in People With Muscular Dystrophy","Transition to Adulthood in People With Dystrophy: Social Cognition Mechanisms, Psychosocial Adjustment, and Mental Health and Coping Strategies.","TAMDY","Inclusion Criteria:\n\n* Defined diagnosis of DMD\n* Age \\> 14 years\n* Willingness and ability to comply to study procedures\n* Comprehension of the study and Signature of the informed consent\n\nExclusion Criteria:\n\n* Clinical history of cerebral palsy, severe intellectual deficit, severe behavioral disturbances\n* absence of compliance to the studyof the patient and the caregivers.","MALE","14 Years",{"count":59,"type":21},250,[24],"The study will involve boys with Duchenne Muscular Dystrophy (DMD), from adolescence to adulthood living in Italy, and their families\u002F caregivers.\n\nThe Investigators want to explore patients' mental health, social cognition and perception of body image as well as patients'and caregivers' ability to adapt to changes related to both the disease and various personal and social needs, through the use of short and simple questionnaires, neuropsychological tests and neurocognitive evaluation in ecological scenarios using Virtual Reality. The desire for autonomy and the awareness of both personal and social difficulties in achieving them put a strain on both patients and their families.Some studies conducted in the USA and in various European countries underline that the transition to adulthood of patients with muscular dystrophy is featured by a good ability to adapt to the more advanced stages of the disease in general; nevertheless, facing the worsening of health entails experiences of anxiety and depression.In this historical phase, clinical trials of gene therapy and gene modulating therapies are involving an increasing number of patients, mainly represented by children in the early phase of the disease. Hence, adolescents and young adults could develop feelings of exclusion from research efforts, losing confidence and hope in any future improvement of their condition, social participation and quality of life.This study could lead to identify strengths and weaknesses in social cognition and psychosocial adaptation; through the evaluation of characteristics of patients\u002Fcaregivers or exogenous factors influencing higher levels of social adaptation, we ultimately aim to define strategies to improve not only physical (already defined by guidelines) but also psychological care, social cognition and social support in all stages of DMD, particularly in later ones.",[27],[64,65,66,67,68],"Duchenne muscular dystrophy","transition to adulthood,","social cognition","psychosocial adjustment","mental health and coping strategies","NOT_YET_RECRUITING","2025-08-01",{"date":72,"type":39},"2025-08-03",{"date":74,"type":21},"2025-09",{"date":76,"type":21},"2027-08",{"name":78,"class":46},"IRCCS Eugenio Medea",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":56,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100583272","social-cognition-in-dystrophinopathies-and-neurodevelopmental-disorders-100583272","NCT06874166","Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders","Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders. Behavioural and Psychophisiological Measures","Inclusion Criteria:\n\n* Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant).\n* Patients diagnosed with osteogenesis imperfecta.\n* Control group: participants without any neurological or psychiatric disorder\n\nExclusion Criteria:\n\n* presence of comorbid diagnoses,\n* sensory deficit\n* specific condition that could prevent the application of the tests and tasks under study, such as: a) the need for PEG; b) the need for tracheostomy; c) the need for assisted ventilation.\n* cognitive level lower than 60.","4 Years",{"count":88,"type":21},45,"OBSERVATIONAL","The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of patients affected by osteogenesis imperfecta (OI), and both compared with a control sample with typical development.\n\nThe secondary aim is to study cortical activity at rest, by means of electroencephalography (EEG), to explore frequencies and time course of EEG responses. Moreover, the relationship between EEG activity and neuropsychological, dispositional and subjective measures will be explored through correlational analyses.",[27,92,93],"Osteogenesis Imperfecta (OI)","Social Cognition",[93,95,92,96,97,98],"Duchenne \u002F Becker muscular dystrophy","EEG","Interpersonal distance","Interoception","2025-03-11",{"date":101,"type":39},"2025-03-13",{"date":74,"type":21},{"date":104,"type":21},"2027-12",{"name":78,"class":46}]